CN101267845A

CN101267845A - Near infrared microbal elimination laser system (NIMELS)

Info

Publication number: CN101267845A
Application number: CNA2006800348723A
Authority: CN
Inventors: E·伯恩斯泰因
Original assignee: NOMIR MEDICAL TECHNOLOGIES Inc
Current assignee: NOMIR MEDICAL TECHNOLOGIES Inc
Priority date: 2005-07-21
Filing date: 2006-07-21
Publication date: 2008-09-17

Abstract

Methods, systems, and apparatus for Near Infrared Microbial Elimination Laser Systems (NIMELS) are disclosed that can apply near infrared radiant energy of certain wavelengths and dosimetry capable of impairing biological contaminants, for example fungus, without intolerable risks and/or adverse effects to biological moieties other than a targeted biological contaminant. Lasers including diode lasers may be used as one or more light sources. A delivery assembly can be used to deliver the optical radiation produced by the source(s) produced to an application region that can include patient tissue. A flat top lens can be included to produce a flat top beam distribution. Exemplary embodiments utilize laser light in a near infrared range of 850nm-900nm and/or 905nm-945nm at suitable NIMELS dosimetry. For certain applications, laser light in two spectral ranges including 870 nm and 930 nm, respectively, can be utilized.

Description

Near-infrared degerming laser system (NIMELS)

Related application

The application relates to the U.S. Provisional Application of following same Applicant and requires its priority, its content is as quoting and complete packet is contained in this: the serial number that on July 21st, 2005 submitted to is No.60/701,896 U.S. Provisional Patent Application " near-infrared degerming laser (NIMEL) system (NearInfrared Microbial Elimination Laser (NIMEL) System) "; The serial number that on August 23rd, 2005 submitted to is No.60/711,091 U.S. Provisional Patent Application " near-infrared degerming laser (NIMEL) system (Near Infrared Microbial Elimination Laser (NIMEL) System) "; The serial number of submitting on March 9th, 2006 is No.60/780,998 U.S. Provisional Patent Application " be used for the treatment of and prevent to point Method and kit for (Method and Apparatusfor the Treatment of and Prevention of Recurrence of Finger and ToenailInfections) with the recurrence of toe nail infection "; And the serial number that on April 4th, 2006 submitted to is No.60/789, and 090 U.S. Provisional Patent Application " is used for the Method and kit for (Method and Device for the UniformIllumination of NIMELS Optical Energy and Dosimetry to a BiologicalContainment in a Biological Moiety) that NIMELS optical energy and exit dose shine equably to the biological pollutant of biology part ".

Technical field

The present invention relates to the method that a kind of selectivity reduces the biological pollutant level in the impact point.The present invention also comprises the treatment pattern, and in particular, relates to the method, apparatus and system of using optical radiation.

Background technology

At present known multiple escherichia coli (E.coli) and other enterococcus (Enterococci) have the resistivity of inherence and immunity for most antibiotics, make it become the important pathogen of human body and Animal diseases.Boyce，et al.，J.Clin.Microbiol.32(5)：1148-53(1994)；Donskey，etal.，N.Engl.J.Med.343(26)：1925-32(2000)；Landman，et al.，J.Antimicrob.Chemother.40(2)：161-70(1997)。The human infection that enterococcus causes comprises endocarditis, bacteremia, and urinary tract infection, wound infection, and abdomen is interior and pelvic infection.Infect for most these classes, antibacterial comes from patient's self intestinal microbial population, and diffusion causes in urethra, the abdomen and surgical wound infection then.Under the serious situation, bacteremia may cause the disseminating apart from the site to more how far subsequently.Whiteside, et al., Am.J.Infect.Control 11 (4): 125-9 (1983); Patterson, et al., Medicine (Baltimore) 74 (4): 191-200 (1995); Cooper, et al., Infect.Dis.Clin.Practice 2:232-9. (1993). recently in the U.S., the medical infection supervision investigation in the whole nation (NNIS) is second inducement to the fourth-largest modal medical treatment infection with the enterococcus rank.Enterococcus frequently causes urinary tract infection, blood infection, and the wound infection of patient in hospital.And enterococcus is the inducement of the bacterial endocarditis case of 5-15%.And, according to report, skin transplantation common association to vancomycin have repellence enterococcus, increased the risk that the relevant sepsis of conduit, cross infection or blood cultivation infect greatly.CDC. national hospital infection supervision (NNIS) System Reports, Am.J.Infect.Control 26:522-33 (1998); Beezhold, et al., Clin.Infect.Dis.24 (4): 704-6 (1997); Tokars, et al., Infect.Control Hosp.Epidemiol.20 (3): 171-5 (1999).Interested especially to the NIMELS laser system is the infectosome of suffering from enterococcus skin or wound infection.Enterococcus infects and relates to almost any skin surface of health, causes for example furuncle, whelk, dermatosiss such as pus born of the same parents and scalded skin syndrome.Staphylococcus aureus (S.aureus) also is the inducement of staphylococcal food poisoning, enteritis, osteomyelitis, toxic shock syndrome, endocarditis, meningitis, pneumonia, cystitis, septicemia and postoperative wound infection.Tomi, et al., J.Am.Acad.Dermatol.53 (1): 67-72 (2005); Breuer, et al., Br.J.Dermatol.147 (1): 55-61 (2002); Ridgeway, et al., J.Bone Joint Surg.Br.87 (6): 844-50 (2005). staphy lococcus infection may be the patient during in hospital or in the long-term treatment facility and produce.Limited crowd and antibiotic widely-used produced to antibiotic have repellence staphylococcus aureus strains.These bacterial strains are called as anti-penicillin staphylococcus aureus (MRSA).The infection that MRSA causes can be resisted multiple antibiotic usually, and has the higher far away sickness rate of the infection that causes than non-MRSA antibacterial, mortality rate, higher cost and longer hospital stays.The risk factor that MRSA infects in the hospital comprise treatment, Critical Care before operation, the antibiotic, be exposed to MRSA builds group's patient or nursing worker, stays in hospital and surpass 48 hours and use inlying catheter or other pass the armarium of skin.Hidron，et al.，Clin.Infect.Dis.15；41(2)：159-66(2005)；Hsueh，et al.，Int.J.Antimicrob.Agents26(1)：43-49(2005)。

These enterococcus and staphy lococcus infection have the very big potential risk that causes central venous catheter CVC to infect, and may cause the very high M ﹠ M of patient.Tomi，et al.(supra)。In fact, data show in the U.S., produces 1,000 5 hundred ten thousand CVC days (promptly selected crowd is exposed to total natural law of CVC during seclected time), Mermel LA., Ann.Intern.132:391-402 (2000) among the annual ICU.The average ratio of this correspondence relevant blood infection of 5.3 CVC of per 1000 conduit days in ICU CDC (above), perhaps in other words, in the relevant blood infection of the U.S. 80,000 CVC of annual approximately generation.Medical institutions are 34 to the cost estimate of each infection cost, 508-56,000 dollar, Rello, et al., Am.J.Respir.Crit Care Med.162:1027-30 (2000); Dimick, et al., Arch.Surg.136:229-34 (2001), and the patient's of the relevant BSI of annual nursing CVC expense is approximately 2.96 hundred million dollars to 2,300,000,000 dollars.Mermel LA.，Ann.Intern.Med.133：395(2000)。

The importance of fungal infection is self-evident in the medical environment.For example, Candida albicans (Candidaalbicans) is considered to infect relevant the seventh-largest most commonly encountered diseases substance with medical treatment among the ICU patient of hospital.Fridkin，et al.，Clinics In Chest Medicine，20：(2)(1999)。For Candida albicans, the treatment selection of accepting usually is polyalkenes antifongin (amphotericin), imidazoles antifongin, and triazole.These therapies need the long time cycle (having system and airframe systems danger simultaneously) mostly, and evidence suggests occurred the opposing antibiotic fungal pathogens.In this case, treatment is selected to become seldom and is limited.

For example, the especially patients that are exposed to azoles therapy or low CD4 counting of acquired immune deficiency syndrome (AIDS) patient have produced the candida albicans infection of resisting azole more.Johnson，et al.，J.Antimicrob.Chemother.35：103-114(1995)；Maenza，et al.，J.Infect.Dis.173：219-225(1996)。The acquired immunity deficiency symptoms of the opposing azole that recently occurs in the acquired immune deficiency syndrome (AIDS) patient is indicating emerging repellence problem in other immunodeficiency patient colony.

These data show, constantly increase to use preventative antifungal therapy may cause improving candida krusei (C.krusei) that fungal pathogens for example has intrinsic azole resistance even the frequency of resisting the C.glabrata or the Candida albicans of azole equally in the patient that the excessive risk endogenetic fungus infects.Maenza，et al.，(supra)；Beezhold，et al.，Clin.Infect.Dis.24：704-706(1997)；Fridkin，et al.，Clin.Microbiol.Rev.9：499-511(1996)；Johnson，et al.，J.Antimicrob.Chemother.35：103-114(1995)。

Continue this bad trend, the data to the U.S.'s 50 tame medical centres in 1998 shows that 10% of the Candida albicans separated has repellence for fluconazole as antifungal medicine from the blood of inpatient.Pfaller，et al.，Diagn.Microbiol.Infect.Dis.31：327-332(1998)。The scope of opposing rate from 5% to 15% depends on the zone of the U.S., show region factors for example the use amount of azole may affect the relative frequency of anti-azoles candida albicans infection.

It is worth noting the infectosome that is called dermatocandidiasis.These monilial infections influence skin, and can occupy all skin surfaces of whole health.Yet modal is warm, humidity or plication region (for example axillary fossa and groin).Dermatocandidiasis is the most common.Huang，et al.，Dermatol.Ther.17(6)：517-22(2004)。Candidiasis is the modal inducement of diaper rash, and it has utilized the favorable environment of warm moist in the diaper.Causing the modal fungus of these infection is Candida albicans.Gallup，et al.，J.Drugs Dermatol.4(1)：29-34(2005)。Monilial infection is also very common in diabetes and obese people.Candidiasis also may cause nail infection, is called tinea unguium, and the infection of the corners of the mouth, is called cheilitis.

Therefore, described document shows that the innovative new treatment of needs solves these infection.

Traditional, in medical science, dentistry and veterinary's subject, used solid-state laser diode visible and near infrared spectrum (600nm to 1100nm) for various purposes, because it has melanin in the biosystem and color are have good absorption curve.Because very poor to the absorption of near-infrared optical energy in water, as seen this radiating penetration of wedged gauge is far longer than or longer infrared wavelength in biological tissue.In particular, the near-infrared laser diode energy can penetrate about 4 centimetres of biological tissue.On the contrary, Er:YAG and CO ₂The emittance with higher relatively water absorption curve that laser produces only penetrates about 15 to 75 microns of biological tissue (10000 microns=1 centimetre).Therefore, by the radiation of near-infrared laser diode, the heat deposition Billy in biological tissue is darker with the situation of middle infrared wavelength.Therefore, it is more effective in cure for treatment of cancer, for example the lacuna LASER HEAT therapy (laser-interstitial-thermal therapy) of degree of depth tumor resection or laser heating sterilization (laser-heat-generated-microbial sterilization).

In order to destroy bacterial cell by visible light and near-infrared laser diode, prior art need be existed the chromogen of external source and/or very narrow treatment window and therapy apparatus meeting by radiant.The blood heat is 37 ℃, and its correspondence produces bacterial growth fast in most bacterial infections.When applying emittance by the near-infrared laser diode, begun to raise the once deleterious physiology contact of 10 ℃ of generations of every rising immediately by the temperature of radiation areas to biosystem.Produce in the time of 45 ℃ and organize overheatedly, enzymatic activity and cell stability reduce in the time of 50 ℃, and protein and collagen degeneration begin to condense in the time of 60 ℃, and cell membrane begins infiltration in the time of 80 ℃, and moisture and biological substance begin vaporization in the time of 100 ℃.Be higher than under 80 ℃ the situation of temperature last very long, (local location 5 to 10 seconds) causes the irremediable injury of healthy cell.

In the prior art, by the near-infrared laser energy photo-thermal of antibacterial is decomposed (thermoinducible decomposition) and need significantly improve temperature, may damage mammalian cell.Yet, need destroy antibacterial by heat usually, and can not cause the irremediable heat injury of mammalian cell.Used laser diode to destroy antibacterial in the prior art with visible laser energy (400nm to 700nm).Need use the external source chromogen to carry out photodynamic therapy to antibacterial point by visible radiation.In the prior art, realized by light power deactivation antibacterial to protokaryon (microorganism) cell and when carrying out radiation by suitable light or lasing light emitter then when applying the external source chromogen.By producing the oxygen-derived free radicals kind to destroy antibacterial with reference to using the visible wavelength be coupled to the external source chromogen, have in the prior art two researchs outstanding especially (with reference to Gibson et al., Clin.Infect.Dis. (16) Suppl4:S411-3 (1993); And Wilson et al., Oral Microb.Immunol.Jun:8 (3): 182-7 (1993) and Wilson et al., J.Oral.Pathol.Med.Sep; 22 (8): 354-7 (1993)).

Therefore, the naturopathy that needs a kind of improvement will be reduced to minimum to the infringement of healthy cell to reduce bacterial growth simultaneously.

Summary of the invention

The invention provides a kind of selectivity target biology pollutant and can not cause method and system the risk that can not tolerate of the other biological outside biological pollutant part (for example mammalian tissues, cell or biochemistry body/prepared product for example protein prepared product) and/or the negative effect that can not tolerate.

The invention provides a kind of method and system, it can apply the near-infrared radiation energy with certain wavelength and exit dose, described energy can damage biological pollutant and can not cause risk that can not tolerate and/or the negative effect (for example losing vigor, perhaps thermal decomposition) to the part of the other biological outside the target organism pollutant that causes in the described traditional method of prior art.Method, apparatus and system of the present invention are called for short NIMELS (being near infrared microbial elimination laser system) expression by initial hereinafter sometimes.

In aspect first, the invention provides a kind of method, it carries out the biological pollutant level that radiation reduces impact point by the light radiation with about 905nm to 945nm wavelength to impact point under the NIMELS exit dose, and can not cause the risk that can not tolerate of the other biological except described target organism pollutant part in the given impact point (for example health tissues, cell or some biochemistry prepared product be the protein prepared product for example) and/or the negative effect that can not tolerate.In certain embodiments, described light radiation can have the wavelength of about 925nm to about 935nm.In the non-limiting exemplary embodiments of Miao Shuing, the wavelength of employing is 930nm hereinafter.According to biological pollutant of the present invention is for example antibacterial, fungus, mycete, mycoplasma, protozoacide, Protein virus, parasite, virus and viral pathogen (viral pathogen) of microorganism.

In aspect second, the invention provides a kind of light radiation that under the NIMELS exit dose, has about 850nm to 900nm wavelength by (a); And the light radiation that (b) has about 905nm to 945nm wavelength is carried out radiation to impact point and is reduced the biological pollutant level of impact point and can not cause method to the risk that can not tolerate of the other biological except described target organism pollutant part in the given impact point (for example health tissues, cell or some biochemistry prepared product be the protein prepared product for example) and/or the negative effect that can not tolerate.With reference to this combined method, and will describe in detail more hereinafter, embodiment of the present invention comprise the wavelength from 865nm to 875nm.Therefore, in the non-limiting typical embodiments of Miao Shuing, the wavelength of employing is 870nm hereinafter.Similarly, for another wave-length coverage, in certain embodiments, light radiation can have the wavelength of about 925nm to 935nm.In the non-limiting typical embodiments of Miao Shuing, the wavelength of employing is 930nm hereinafter.

In the method aspect this according to the present invention, can be with separately (pulse or CW), (pulse or CW) or the basic mode of (pulse or CW) simultaneously utilize related wave-length coverage to carry out radiation in turn.

In aspect the 3rd, the invention provides the system of the method for a kind of the present invention of realization first and second aspects.Described system comprises and is used to produce radiating laser oscillator, is used to calculate and control the controller of described radiating dosage, and is used for by the application region the transmission head of described radiation delivery to point of care.

In one form, described system can utilize dual wavelength near-infrared solid-state laser diode, and what described laser diode was preferred and nonessential can be arranged in single encapsulation, has unified control.Described two wavelength can be included in the emission in two scopes of about 850nm to 900nm and 905nm to 945nm.The present invention can also use laser oscillator to launch single wavelength in any one scope that the present invention comprises.In certain embodiments, can use described laser with the emission radiation in 865-875nm and 925-935nm scope basically, this will carry out more detailed description with second aspect with reference to of the present invention first.In this example system is embodiment in order to show that the present invention is possible fully.Described system design is essentially the radiating system of 870nm and 930nm for emission.

Can comprising of described optimum system choosing at the solid-state diode of each independent wave-length coverage or at variable ultrashort pulse laser oscillator and/or the dopant ion optical fiber or the optical fiber laser of two wave-length coverages.In one form, described near-infrared laser comprises titanium-doped sapphire.

According to an embodiment of the invention, described therapy system comprises that optical radiation produces equipment, be suitable for producing the optical radiation in first wave-length coverage substantially from about 850nm to about 900nm, transfer device is used to cause described optical radiation to transmit by the application region, and the exercisable controller that is connected to described optical radiation generation equipment, be used to control radiation dose, thereby the time integral of radiating power density of the transmission of unit are and energy density is lower than predetermined threshold by the transmission of described application region.According to this embodiment of the present invention, also relate to the therapy system that is particularly suitable for producing basic optical radiation in first wave-length coverage from about 865nm to about 875nm.

According to another embodiment, described optical radiation produces equipment and further is configured to produce basic in the optical radiation in second wave-length coverage of about 905nm to 945nm.According to this embodiment of the present invention, also relate to the therapy system that is particularly suitable for producing complete optical radiation in first wave-length coverage from about 925nm to about 935nm.Described therapy system comprises that further transmission system is used for the optical radiation in described second wave-length coverage transmission by the application region, and controller is used to control described optical radiation and produces equipment and produce substantially in described first wave-length coverage and/or basic radiation in described second wave-length coverage with selectivity.

According to further embodiment, the controller of described therapy system comprises that load limiter is used to control described radiating dosage.Described controller may further include memorizer and is used for store patient data and exit dose and calculates device and be used for based on the information of operator's input and calculate the required dosage of specific objective point.In a preferred embodiment, described memorizer also can be used to store the information about dissimilar diseases and treatment data, for example related with application-specific radiating pattern and radiating dosage.

Described optical radiation can be passed to point of application with different mode from described therapy system.For example, by single wavelength mode or dual wavelength pattern, in described dual wavelength pattern, the radiation of two wavelength is by multiplexed or transfer to identical point of care simultaneously.Optionally, described radiation can be transmitted by alternate mode, and wherein the radiation of two wavelength alternately is delivered to identical point of care.Can be one or more pulse at interval.Each treatment can be carried out combination in any to these transmission modes.

To provide other targets of the present invention, feature and advantage below in detailed description of preferred embodiment, can understanding by following description of these feature and advantage parts perhaps can be understood by enforcement of the present invention.These targets of the present invention and advantage can realize and obtain by the system, the method and apparatus that particularly point out in description and claims.

The accompanying drawing summary

For the complete understanding system and program of the present invention more, be described in detail below with reference to the accompanying drawings, wherein:

Fig. 1 shows power density (vertical coordinate) to illustrate with respect to the double-log that is the radiated time (abscissa) of unit second.Main laser-tissue interaction is depicted as the different energy density thresholds and the function of parameter.Diagonal is represented different energy density, has shown the energy density values (reference identification is the annular region of NIMELS) that adopts according to the present invention.

Fig. 2 has shown the sketch map of system in accordance with a preferred embodiment of the present invention;

Fig. 3 a-3d has shown the different mode of the light radiation that produces by therapy system shown in Figure 2;

Fig. 4 uses the diagram of the typical external efficacy data (according to killing percentage rate) of typical method of the present invention, equipment and system's acquisition with respect to the target Bacillus coli cells down in different total energy value (unit is joule);

Fig. 5 uses the diagram of the typical final sample temperature that typical method of the present invention and systematic observation arrive (unit for ℃) with respect to the target Bacillus coli cells down in different total energy value (unit for joule);

Fig. 6 uses the diagram of the typical final sample temperature that typical method of the present invention and systematic observation arrive (unit for ℃) with respect to the target aureus cell down in different total energy value (unit for joule);

Fig. 7 is a diagram of using the typical external efficacy data that typical method of the present invention and systematic observation arrive under can the temperature of heat tolerance by therapeutic goal point;

Fig. 8 is meant the diagram of nail body, has shown nail matrix (parent), deck and paronychium.Nail matrix is side and comprise blood vessel and nerve belowdecks.Comprise the germinal matrix (germinal matrix) and the non-germinal matrix (sterile matrix) that produce most of fingernail keratinization volume in the nail matrix.This substrate (matrix) is " root " of fingernail, and its most of tip part is visible on most fingernails, promptly is called as the semilune structure of lunula of nail;

Fig. 9 is the diagram that shows typical tinea unguium patient's fingernail, has shown that deck, nail matrix (non-germinal matrix and germinal matrix) and fingernail fold (lunula of nail that the eponychium below grows) zone begins to improve in several weeks after initial therapy according to an embodiment of the invention;

Figure 10 is the diagram that shows the chronic infection fingernail, has also shown the characteristic symptoms relevant with chronic paronychia (for example infect on the top layer in the paronychium).May produce paronychia and infect when the confining bed between near-end fingernail fold and the deck breaks, this confining bed breaks and has opened the inlet of biological invasion tissue.Chronic paronychia causes swelling, rubescent, fragile and mixed and disorderly fingernail fold, and the symptom of this disease continues six weeks or longer and the tinea unguium of accompanied by long-term;

Figure 11 is the diagram that shows some tinea unguium patient's fingernail, has shown the different discrete areas of the fingernail that is subjected to courses of infection, and other zones of complete uninfection, and the healthy part of its middle deck is still hard and translucent;

Figure 12 a and c show with area to be that 1.77 square centimeters incident Gaussian beam is to the sketch map of the irradiation mode of 1.5 centimetres radiant.As shown in the figure, by the Gaussian Energy Distribution pattern, in 1.77 square centimeters radiation areas, there are six different power density intensity at least.The power density of these variations constantly strengthens (being power concentration) from putting 1 (periphery) to putting 6 (center) intensity on surf zone.The demonstration that Figure 12 b and 12d are opposite in certain embodiments of the invention by the NIMELS system in vivo in the body and the uniform Energy distribution of external use (" carnival hat (Top-hat) " pattern);

Figure 13 is the diagram that shows for the Tn function of given point of irradiation dimensional parameters (diameter is 1.2-2.2 centimetre), and treatment time passes through energy density 409J/cm ²Divided by the power density under 3.0 watts of the laser output powers and draw.Therefore, NIMELS (time) parameter=Tn=409/ power density;

Figure 14 is the diagram that shows for the Tn function of given point of irradiation dimensional parameters (diameter is 1.2-2.2 centimetre), and treatment time, parameter was by with energy density 205J/cm ²Divided by the power density under 3.0 watts of the laser output powers and draw.Therefore, NIMELS (time) parameter=Tn=205/ power density;

Figure 15 shows the constitutional diagram of the typical tinea unguium patient's who treats according to the inventive method fingernail outward appearance along with the time improvement.

The specific embodiment

Constituted those skilled in the art's knowledge and all be incorporated by reference thereto in this patent of quoting, open application and scientific literature, as all being special separately to be incorporated into this as a reference.Conflict between any description of this any reference of quoting and this description should solve according to the latter.Same, this area definition of any term and the conflict between the definition of this description should solve according to the latter.

Technology and scientific terminology have and the common meaning of understanding of those skilled in the art in the invention (unless special definition) as used herein.At this whole bag of tricks and material known to those skilled in the art are carried out reference.The canonical reference document of describing the microbiology general principles comprises: Joklik et al., ZinsserMicrobiology, 20 ^ThEd, Appleton and Lange (Prentice Hall), East Norwalk, Connecticut (1992); Greenwood et al., Medical Microbiology, 16 ^ThEd., ElsevierScience Ltd., New York (2003); Sambrook et al., Molecular Cloning:ALaboratory Manual, 2 ^NdEd., Cold Spring Harbor Laboratory Press, New York, NY (1989); Kaufman et al., Eds., Handbook of Molecular and Cellular Methodsin Biology in Medicine, CRC Press, Boca Raton, FL (1995). the canonical reference document of describing pharmacology's general principles comprises: Goodman and Gilman ' s The Pharmacological Basisof Therapeutics, 10 ^ThEd., McGraw Hill Companies Inc., New York, NY (2001). the dermatosis principle of standard can be with reference to Habif et al., Skin Disease, Diagnosis andTreatment, 1 ^StEd., Mosby, Inc, St.Louis, MO (2001).

The invention provides the method, apparatus and system of the near-infrared radiation energy of using certain wavelength and certain exit dose, it can damage the target organism pollutant, simultaneously the biological part outside the target organism pollutant is had minimum risk.Described method and apparatus/system can't produce or depend on the temperature that can not the tolerate rising (i.e. heating) that is associated with the traditional method of this area.

The near-infrared radiation energy is used in the art that (Ashkin et al., Nature330:769-771 (1987) are used for keeping at various needs the application operation and the control biological targets of operated cytoactive as optical tweezers.A lot of reports show that the use near-infrared radiation usually is associated with " optics cutting " as tweezers, perhaps briefly be exactly pair cell bad injury (for example by can quantized activity and the reduction of breeding measure) (Ashkin and Dziedzic, Ber.Bunsenges., Phys.Chem.93:254-260 (1989)).Injure in the effort of cytoactive avoiding optimizing optical tweezers, the action spectrum of having found photodamaged 870 and the 930nm place present maximum (Neuman et al., Biophys.J.77:2856-2863 (1999)).Class likelihood data in Chinese hamster ovary (" the CHO ") cell is (for example with reference to Liang et al., Biophys.J.70:1529-1533 (1996)) there be (Neuman et al., Biophys.J.77:2856-2863 (1999)) equally in the wavelength dependency of the photodamaged that causes research worker to be believed finding in the prokaryotic cell in eukaryotic cell.Therefore the common recognition in this area be its wavelength near or the near-infrared radiation that equals the maximum 870 discerned and 900nm cause the cell injury of protokaryon (for example antibacterial) and eucaryon (for example CHO) cell.

Use near and equal 870 and the radiating more deep research (hereinafter describing) of 900nm maximum illustrated the optical parametric (being wavelength, power density, energy density and open-assembly time) that is associated with remarkable different-effect on the impact point (for example cell).Use these exit dose parameters, can use near-infrared radiation processing target biological pollutant, even and simultaneously to the other biological just slight influence that partly exerts an influence also.Obviously, this discovery has a lot of useful practical applications.

In particular, have been found that in some exit dose parameter approximately the energy of the wavelength in the scope of 905nm to 945nm is suitable for the biological pollutant in the selectively targeted impact point and can cause the risk that can not tolerate of the part of the other biological except the target organism pollutant and/or the negative effect that can not tolerate in the given impact point.

Therefore, in aspect first, the invention provides a kind of method, it carries out the biological pollutant level that radiation reduces impact point by having from the light radiation of the wavelength of about 905nm to 945nm to impact point, and can not cause the risk that can not tolerate of the other biological except described target organism pollutant part in the given impact point (for example health tissues, cell or some biochemistry prepared product be the protein prepared product for example) and/or the negative effect that can not tolerate.In certain embodiments, described light radiation can have the wavelength of about 925nm to about 935nm.In the non-limiting exemplary embodiments of Miao Shuing, the wavelength of employing is 930nm hereinafter.

Find also that simultaneously for the light radiation of about 905nm to 945nm impact point being carried out effect that radiation obtains by wavelength can strengthen by adopting wavelength carry out radiation for about at least one additional optical radiation of 865nm to 875nm.As described here, obtain required gross energy and the density of required different-effect on the impact point that combination radiation is treated by being reduced in, thereby further strengthened the radiating effect of 905-945nm scope.This finds particular importance, because it has reduced the radiation in the 905-930nm scope that obtains required effect needs.Therefore, the attendant advantages of this combination radiation method is further to have minimized the risk that can not tolerate of the biological part outside the target organism pollutant and/or the negative effect that can not tolerate.

When standing (a) from about 850nm to 900nm with (b) from two kinds of wavelength of about 905nm to 945nm, impact point produces this synergism.In some typical and non-limiting embodiment of this example, find wavelength in the 865-875nm scope radiation strengthened the radiating effect of wavelength in the 925-935nm scope.In certain embodiments, impact point is exposed to the radiation of λ=870 and λ=930nm, has reduced required gross energy and density simultaneously.

Aforesaid NIMELS wavelength (for example 850-900nm and 905-945nm) can be used for separately, in turn and/or basic simultaneously mode radiation target point.

Term " reduction biological pollutant level " expression reduces the level of at least a active biological contaminants that exists in the impact point of the treatment according to the present invention as used herein.Rule of thumb, the reduction of biological pollutant level is quantified as the vigor reduction (for example by damaging vigor and/or its growth and/or the splitted ability of biological pollutant) of the biological pollutant in the impact point.It will be understood by those skilled in the art that expression way " reduces the biological pollutant level " and comprises that any degree reduces and might not be 100% reduction.In fact, in certain embodiments, the activity of given biological pollutant may only be reduced to allow other situations that (for example allowing the reaction of patient's immune system to given infection, perhaps allow other Synergistic treatments---for example systemic antibiotic therapy---to solve given infection) takes place by part.In some examples, find that given biological pollutant is strengthened after treatment according to the present invention the susceptibility of antibacterial.In a particular embodiment, the MRSA mutation is found after treatment according to the present invention antibiotic susceptible (data not shown) more.

Such biological pollutant represented in term " biological pollutant " as used herein, it is in case direct or mediate contact impact point (for example patient's infected tissue or organ) promptly can cause bad and/or harmful effect to impact point or near the mammal (for example being transplanted to cell, tissue or the organ of receptor or the equipment that uses the patient on one's body) of impact point.According to biological pollutant of the present invention is microorganism, for example antibacterial, fungus, mycete, mycoplasma, protozoacide, Protein virus, parasite, virus and viral pathogen, as well known to those skilled in the art they in impact point, be found usually according to the present invention.It will be understood by those skilled in the art that method and system/equipment of the present invention can use (for example with reference to Joklik et al., (supra) in conjunction with various biological pollutants as known in the art; AndGreenwood et al., (supra)).Below tabulation only be for example method and apparatus according to the invention/system can targeting the broad range of microorganism, be not to limit range of application of the present invention by any way.

Therefore, the non-limiting example of biological pollutant comprises any antibacterial, Escherichia for example, enterobacteria, bacillus cereus, Campylobacter, excellent bacillus, klebsiella, treponema bacterium, vibrio, streptococcus and staphylococcus.

For further example, biological pollutant comprises any fungus, candidiasis for example, aspergillosis, cryptococcus, various dermatophytess (for example Trichophyton, sporidiole bacteria and epidermophyton), ball spore bacterium, histoplasma capsulatum, blastomyces.Parasite also can be the target organism pollutant, and for example trypanosoma and plasmodium comprise plasmodium family, and mycete; Mycoplasma; Protein virus; And virus, for example HIV (human immunodeficiency virus) and other retroviruss, herpesvirus, parvovirus, Filovirus, cyclic conformation virus, paramyxovirus, cytomegalovirus, hepatitis virus (comprising hepatitis B and hepatitis C), poxvirus, toga virus, Epstein-Barr virus and parvovirus.

Should be appreciated that and treat that radiating impact point is not necessarily infected by biological pollutant.Method of the present invention can " preventative " be used (promptly being used for prevention) before infecting.

In these examples, radiation can be for curative and preventative.Therefore, method of the present invention can be used for the certain therapeutic effect time quantum of radiation physiological tissue, thus treatment or alleviation infection symptoms.The symptom that reduces, prevents and/or reverse the individuality of being treated according to the present invention is compared in expression way " treatment or alleviation " expression with the symptom of the individuality of not accepting described treatment.

The doctor is appreciated that method described here is used in combination with doctor's (doctor or veterinary) lasting clinical assessment to determine successive treatment.Therefore, after treatment, the doctor will be according to any improvement of standard method assessment treatment basic condition.These assessments will assist and inform whether increase, reduce or continue specific therapeutic dose, radiation mode and additional treatment or the like.

As described in this manual, any cell, tissue, organ, object or the solution that may be polluted by biological pollutant of term " impact point " expression.Therefore, impact point can be mammiferous cell, tissue or organ, may be infected by biological pollutant, brings danger to mammal.Optional, impact point can be mammiferous cell, tissue or organ, may be infected by biological pollutant, bring danger (for example under the situation of the cell of in the receptor mammal, implanting, tissue or organ, perhaps under the situation of the equipment that uses on the mammal) near the mammal of impact point.The most important thing is mankind's (the present invention is not limited thereto) in these mammals, and can be applied to veterinary applications.Therefore, according to the present invention, " mammal " or " mammal that needs " or " patient " comprise the mankind and non-human mammal, particularly performing animal, include but not limited to cat, Canis familiaris L., horse.

It will be understood by those skilled in the art that the present invention for various by microorganism, fungus and viral infection cause or related with it disease particularly useful (with reference to Harrison ' s, Principles ofInternal Medicine, 13 ^ThEd., McGraw Hill, New York (1994)).In certain embodiments, the method according to this invention and system can work in coordination with available traditional therapy in this area and use (for example with reference to Goodman and Gilman ' s (supra)) to infect by applying existing antimicrobial agent treatment.Term " antimicrobial compositions ", " antimicrobial medicament " expression can apply and suppress the synthetic medicament (for example antibacterium type, antifungal type and anti-virus type) of the diffusion of infected by microbes to the mankind or animal.

Range of application for example comprises various dermatosiss, pedopathy widely, department of pediatrics is sick and various other diseases.

Various skin condition of illness condition (for example with reference to Habif et al. (supra)) can be treated by the method according to this invention, equipment/system.The present invention is not limited to following listed specific infection, and for example, the present invention can be used for the treatment of corynebacterium and infect, and this infection can cause erythrasma, oxter trichomycosis and pitting keratolysis (pitted keratolysis); Staphy lococcus infection, this infection can cause impetigo, ecthyma and folliculitis, and streptococcal infection, this infection can cause impetigo and erysipelas.Erythrasma is to be infected by the epidermis that corynebacterium causes, and takes place in narrow space usually.Impetigo is the common infection of child, also may take place in the adult.It is normally caused by staphylococcus aureus or streptococcus.Ecthyma takes place in overwrought crowd, and for example diabetes are controlled very poor patient, and is caused by the mechanism identical with causing impetigo usually.Folliculitis patient presents little yellow pustule in root of hair portion, particularly at scalp, back, shank and arm place.Furuncle is more serious folliculitis.Erysipelas presents acute erythema, infected area pain and enlargement.This disease is considered to be caused by the beta-Streptococcus hemolyticus usually.With reference to Trueb et al., Pediatr Dermatol 1994; 11:35-8 (1994); Trubo et al., Patient Care 31 (6): 78-94 (1997); Chartier et al., Int.J.Dermatol.35:779-81 (1996); And Eriksson et al., Clin.Infect.Dis.23:1091-8 (1996).

Similarly, fungus and yeast PI skin histology, cause various symptoms (dermatomycosis), can solve according to the present invention, for example comprise tinea capitis, tinea barbae, shank tinea, the tinea manuum, (with reference to Ansari et al., LowerExtremity Wounds 4 (2): 74-87 (2005) for tinea pedis and groin (unguium) tinea (with reference to the tinea unguium of hereinafter discussing); Zaias, et al., J.Fam.Pract.42:513-8 (1996), Drake et al., J.Am.Acad.Dermatol.34 (2Pt 1): 282-6 (1996); Graham et al., J.Am.Acad.Dermatol.34 (2pt 1): 287-9 (1996); Egawa et al., SkinResearch and Tech.12:126-132 (2005); And Hay, Dermatol.Clin.14:113-24 (1996)).The for example common infection that takes place based on the candidiasis substance of a crease in the skin and diaper zone of wet area.The skin wound that wooden fragment or thorn cause may cause sporotrichosis (with reference to Kovacs et al., Postgrad Med 98 (6): 61-2,68-9,73-5 (1995)).Candida albicans and Trichophyton, epidermophyton, sporidiole bacteria, aspergillosis and horse traction color mycete are common infected tissues (with reference to Masri-Fridling, Dermatol.Clin.14:33-40 (1996)).

HPV (human body papillomavirus) also may cause skin infection, and depending on infected surface and relative humidity thereof may be dissimilar warts by clinical diagnosis.Usually the wart that takes place comprises common wart, sole wart, teenager wart and condyloma latum.Also there is not at present customary effectively Therapeutic Method (Sterling, Practitioner 239:44-7 (1995)) at the standard of wart.

As institute's example hereinafter, the present invention can be used for the treatment of tinea unguium, i.e. the disease (for example fungal infection) on the deck of finger or toe." fingernail " comprises one of the fingernail complex or some or all parts as used herein, comprise deck (horny layer, the hard skin that compacts of fingernail, be the visible part of fingernail), nail matrix (the cuticle region of below, deck, grow thereon in the deck), eponychium (coated deck and at the tissue of fingernail root fringing), first fold (at three frameworks and support a crease in the skin of fingernail), lunula of nail (the white semilune part of fingernail root), substrate (the invisible part of epidermis below fingernail), and hyponychium (hyponychium) (the thickization epidermis of fingernail free terminal below) and nail matrix (nail matrix).Fingernail is grown from parent.Fingernail mainly is made up of keratin, sclerosis protein (also existing in skin and hair).Along with new cell is grown from parent, old cell is pushed away, compresses and becomes flat, hard fingernail or the toenail that we are familiar with.

Tinea unguium may be caused Trichophyton, sporidiole bacteria, epidermophyton by three kinds of dermatophytess, candidiasis, (modal is Candida albicans, and/or mycete, for example little broom sample mycete (Scopulariopsisbrevicaulis), Fusarium, Eurotium, chain lattice spore, a top spore, Scytalidinumdimidiatum (Hendersonula toruloides), Scytalidinium hyalinum.) one or more toenail of tinea unguium PI and/or fingernail, and normally big toe or little toe.It may present one or more different symptoms, for example horizontal tinea unguium (lateral onychomycosis) (side at fingernail presents white or yellow opaque striped), subungual hyperkeratosis (subungualhyperkeratosis) (below fingernail, forming scale), and terminal onycholysis (distal onycholysis) (when the fingernail end to upper process).Common clinical discovery comprises break (for example top layer white tinea unguium) of free edge, laminar white dot that the deck forms above and concave point (for example terminal tinea unguium), the yellow spotting that the first quarter moon zone occurs, and the destruction fully of fingernail (with reference to Sehgal and Jain, Inter.J.of Dermatol.39:241-249 (2000); Hay, JEADV19 (Suppl.1.): 1-7 (2005); Warshaw et al., Inter.J.ofDermatol.44:785-788 (2005); Sigureirsson et al., J.of Dermatol.Treatmt.17:38-44 (2006); Rodgers et al., Amer.Fam.Phys. (referring to http://www.aafp.org/afp/20010215/663.html); Lateur, J.of Cosmet.Dermatol.5:171-177 (2006)).

Be readily appreciated that, the method for any known clinical symptoms that solution is associated with tinea unguium and tinea corporis also is provided according to treatment of the present invention.The a large amount of patients that infected by tinea unguium are lacked effective treatment patient's quality of life has been caused have a strong impact on, cause serious psychology and social mentality's consequence (for example with reference to Elewski et al., Int.J.Dermatol.36:754-756 (1997)).Treatment according to the present invention provides confessed these diseases in this area to self-image and dysgenic effective alleviation of whole quality of life.

Report in this area shows that also fungal infection (for example fungal infection of nail) is a risk factor of antibacterial tissue infection, for example comprise infection (for example with reference to Roujeau etal., Dermatology 209:301-307 (2004)) such as acute antibacterial cellulitis.Therefore the new method that treatment of fungal infections is provided the inhibition Secondary cases or followed sexuality to dye described here.

The tinea unguium of diabetics and tinea corporis may cause infecting, and particularly the antibacterial sepsis may cause life danger, because diabetics suffers superinfection (for example with reference to Rich, J.Am.Acad.Dermatol.35:S10-12 (1996)) easily.For the patient who suffers from unstable diabetes, the candidiasis of recurrence may cause the candidiasis sepsis, and finally may cause the candidiasis paronychia, further worsen the Onychodystrophy (for example with reference to Millikan et al., Int.J.Dermatol.38 (2): 13-16 (1999)) that long-standing tinea unguium causes.

By virus chronically infected a large amount of fingernails also suffer usually chronic or acute paronychia (with reference to Rockwell, American Med.Physic.63 (6): 1113-1116 (2001); And Grover et al., Dermatol.Surg.32:393-399 (2006)).Chronic paronychia is that the local surfaces of paronychium (epidermis around the fingernail) infects.Break when the fingernail fold of near-end and the enclosure portion between the deck and paronychia can take place when producing the invasion inlet and infect.Chronic paronychia is normally apyogenous, and is difficult to cure.Chronic paronychia causes swelling, rubescent, fragile and mixed and disorderly fingernail fold, and the symptom of this disease continues six weeks or longer and the tinea unguium of accompanied by long-term.The virus of bringing out this disease is candidiasis normally.

According to some embodiment, method and apparatus/system of the present invention can be in conjunction with applying the pharmaceutical active medicament and/or comprising the compositions of pharmaceutical active medicament and use.These medications can be for systems or are partial.Be suitable for these antifungal pharmacy active agents of system's (for example oral or injecting drug use) or partial (for example ointment, cream, spray, gel, lotion and patch) and compositions and be in the art known (for example with reference to United States Patent (USP) 4,755,534,6,121,314,4,680,291,5,681,849,5,856,355, terbinafine and the United States Patent (USP) 5 described in 6,005,001,633,015,4,727,064, the itraconazole of describing in 5,707,975).

As what describe hereinafter, resisting antibiotic antibacterial can the effectively treatment by the method according to this invention.And method of the present invention can be in conjunction with traditional method, substitute traditional method or even use the effect that strengthens traditional method as effective treatment means in turn with traditional method.Therefore, the present invention can combine with antibiotic therapy.Term " antibiotic " includes but not limited to β-lactam penicillin and cephamycin, vancomycin, bacitracin, macrolide (erythromycin), ketone lactone (Ketek), but woods amine (clindomycin), chloromycetin, tetracycline, aminoglycoside (gentamycin), amphotericin, cefazolin, clindamycin, mupirocin, sulfonamide, trimethoprim, rifampicin, metronidazole, quinolones, novobiocin, many glutinosins, azoles alkane family (for example Linezolid), glycylglycine (for example tigecycline), cyclic lipopeptide (for example daptomycin), pleuromutilin (for example retapamulin) and Gramicidin or the like and any salt and mutation thereof.It should also be understood that, tetracycline includes but not limited to immunity ring plain (immunocycline), duomycin, oxytetracycline, demeclocycline (demeclocycline), methacycline, doxycycline and minocycline or the like, all within the scope of the present invention.It is also understood that further aminoglycoside antibiotics includes but not limited to gentamycin, BBK8 amikacin and neomycin or the like, all within the scope of the present invention.

Comprise in conjunction with the known method of the other treatment infected by microbes of method, apparatus and system described here and to use suitable Medical dressing.The internal's of ill or injured parts of skin or human body or animal any cover layer, protective layer or supporting layer represented in term " Medical dressing " as used herein.Described dressing can for but be not limited to absorbent dressing, gauze for example, antiseptic gauze or absorbability Cotton Gossypii, the antiseptic dressing of permeable germicidal solution to postpone or to protect from infection, dry dressing, for example dry gauze dry absorbs Cotton Gossypii or can be by well known to a person skilled in the art any way sterilization and can not causing this dressing can not place any other drying material on the open wound.The Medical dressing of indication of the present invention can also comprise non-sticky dressing; can not stick on the infected wound, protectiveness dressing prevents the further infection or injured of the infected part of health; and moist dressing, wherein this dressing was soaked before being applied to infected point.Term " Medical dressing " may further include the supporting layer based on oil, and for example vitamin e has wherein dissolved according to antibiotic complex of the present invention.For example can form obstacle at the bottom of the oil base such as vitamin e stops further infected by microbes and antibiotic complex is imported the tissue that is damaged.

In some cases, the method according to this invention, equipment and system can be used for given effect product sterilization/sterilize or keep given product " aseptic " fully.Therefore, impact point also can be an object, armarium (for example conduit or stenter) for example, artificial prosthetic appliance (for example artificial joint).

Biomembrane on the armarium of keeping somewhere may comprise Gram-positive or gram-negative antibacterial or fungus group.Gram-positive organism on the armarium biomembrane comprises enterococcus faecalis (E.faecalis), staphylococcus aureus, staphylococcus epidermidis, and S.viridans.Gram negative bacteria comprises escherichia coli, Klebsiella Pneumoniae, proteus mirabilis, and bacillus pyocyaneus.These antibacterials usually may from patient skin or healthy nursing staff, tap water that inlet exposes or the environment other originate patient oneself for example stool and produce.

Produce bacterial biof iotalm when attaching to moist surface (for example inner chamber of conduit) when microbial organisms is irreversible, and produce extracellular polymer, it can assist to depend on and provide the array of structures of colony.The formed surface of biomembrane may be inert, non-living material or biological tissue.Microbial organisms in the biomembrane is being different from planktonic bacteria (freely suspending) aspect the ability of the speed of growth and opposing antibiotic therapy, and finally brings a very big medical treatment and a public health difficult problem.The present invention can suppress planktonic bacteria and attach to the surface of armarium and therefore prevent to form bacterial biof iotalm.

Contaminated indwelling armarium can not form biomembrane and also be subjected to a plurality of factor affecting.Key step is that antibacterial or fungus must attach to the exposed surface long enough time of equipment to become irreversible depending on.As an example of this problem, catheter (tubular rubber or silicones equipment) is easy to produce biomembrane on catheter interior or outer surface when inserting.Usually polluting these equipment and producing biomembranous organism is staphylococcus epidermidis, enterococcus faecalis, escherichia coli, proteus mirabilis, bacillus pyocyaneus, Klebsiella Pneumoniae, and other Gram-negative organisms.The time that catheter stops is long more, and these organisms produce biomembrane and cause the probability of urinary tract infection big more, cause very big medical care problem.

Prior art has advised that multiple mode prevents to produce biomembrane in conduit.Traditional method is included in and uses strict aseptic technique in the implantation process, carry out partial sterilization in the insertion point, minimize conduit and insert the time, adopt built-in filter that IV fluid is filtered, the manufacturing machine obstacle flows into to stop organism by the inlet that conduit is attached to the operation implantation, and attempts applying the antibiotic medicament at conduit cavity.Yet, do not have a kind of effect of art methods satisfactory.

The method according to this invention, equipment and system can use together in conjunction with keeping somewhere armarium, for example central venous catheter and Needleless connector, and tracheal tube, peritoneal dialysis catheters, myringotomy conduit and catheter, thus prevent to form biomembrane.

The present invention can also be used to handle biochemistry or chemical material, and these materials are infected (biological example chemistry or liquid medicine) by biological pollutant.The most methods that is used for producing the preparation (for example immunoglobulin preparation) that uses mammal in this area may cause these products by viral pollution (being biological pollutant).For example, monoclonal immunoglobulin preparation has three kinds of modes of production usually.In cell culture system, produce for first kind, second kind use animal as interim bioreactor producing monoclonal immunoglobulin, thereby and the third gene with required monoclonal immunoglobulin insert animal and make and cause in a fluid or tissue kind of the lasting production monoclonal immunoglobulin of animal and can constantly extract (gene change produce).Under the situation of first method, the cell of production monoclonal immunoglobulin can be carried at the undetected virus that produces in the culture systems.All the other two kinds of methods relate to use animal to produce the host of cell as monoclonal immunoglobulin or as bioreactor so that himself makes monoclonal immunoglobulin.Obviously, these products are faced with the risk that the pathogen that infected or carry by host animal is polluted.These pathogen comprise virus, antibacterial, yeast, mycete, mycoplasma and parasite or the like.Therefore, the monoclonal immunoglobulin product kills any biological activity pollutant wherein extremely important before use.This seems and is even more important when this product directly imposes on the patient.For this is also extremely important for the various monoclonal immunoglobulin products that comprise various types of blood plasma and may suffer to produce in the medium of mycoplasma or other viral pollutants.

In the virus that human and animal's biological preparation is paid close attention to, minimum virus is parvovirus (Parvoviruses) and big slightly slightly is the hepatitis virus of protein bag quilt.In the mankind, assays for parvovirus B 19 and hepatitis A virus and bigger and more softish virus for example HIV, CMV, hepatitis B and hepatitis C virus and other virus are the objects of paying close attention to.In the product and tissue that pig generates, minimum corresponding virus is the parvovirus of pig.

Interaction between the impact point of being treated and the energy of input comprises: wavelength by the quantity of parameters definition; The chemistry of impact point and physical attribute; The power density of wave beam or amount of radiation; What use is continuous wave (CW) or impulse radiation; The laser beam spot size; Open-assembly time, energy density, and any variation of the physical attribute of the impact point of the laser emission correspondence by these parameters.And the physical attribute of impact point (for example absorption and scattering are sparse, scattering anisotropy, heat conductivity, thermal capacity, and mechanical strength) also may influence whole structure.

Term " NIMELS exit dose " expression power density (W/cm ²) and energy density (J/cm ²) value, under these values, can reduce the biological pollutant level in the impact point and can not cause the partly risk that can not tolerate of (for example mammalian cell, tissue or organ) and/or the side effect that can not tolerate of the other biological except biological pollutant according to target wavelength of the present invention.

(part is replicated in Boulnois as shown in Figure 1, Lasers Med.Sci.1:47-66 (1986)), under low power density (being also referred to as luminous) and/or energy, the interaction of laser-tissue can be described to pure optical (photochemical), and issues third contact of a total solar or lunar eclipse thermal interaction in higher power density.In the example embodiment of Miao Shuing, in traditional zone that photodynamics is treated in conjunction with external drug, dyestuff and/or chromophore that is used for, NIMELS exit dose parameter is (with reference to figure 1) between known photochemistry and photo-thermal parameter hereinafter.

As shown in Figure 1, depend on described interaction, the energy density (flow) that is used for the medical laser application in this area is usually at 1J/cm ²And 10000J/cm ²Change between (five exponent number magnitudes), and power density (luminous) is 1 * 10 ^-3W/cm ²To surpassing 10 ¹²W/cm ²Change between (15 exponent number magnitude).In case make reciprocal relevant (reciprocalcorrelation) between power density and illumination open-assembly time, all need about identical energy density for the interaction of any required specific laser-tissue.Therefore, the laser exposure persistent period (light application time) is the interactional character of decision laser-tissue and the parameter of safety.For example, on mathematics, seek the laser-tissue interaction (based on Boulnois 1986) of the heat vaporization (non-ablative (non-ablative)) of in-vivo tissue if desired, can see, in order to produce 1000J/cm as particular treatment ²Energy density (in heat vaporization shadow region), should use any one of following exit dose parameter:

Table I: the example value that draws based on Boulnois table

Power density	Time	Energy density
Power density	Time	Energy density		1×10 ⁵W/cm ²	0.01sec.	1000J/cm ²
1×10 ⁴W/cm ²	0.10sec.	1000J/cm ²		1×10 ⁵W/cm ²	0.01sec.	1000J/cm ²
1×10 ⁴W/cm ²	0.10sec.	1000J/cm ²	1×10 ³W/cm ²	1.00sec.	1000J/cm ²

This part has been described rudimentary algorithm to use NIMELS to interact at the biological pollutant in the tissue.In other words, this mathematical relationship is that the reciprocal of interaction phenomenon of realizing laser-tissue is correlated with.This logic is passed through NIMELS energy observed antibiotic phenomenon (by experiment) when inserting the NIMELS experimental data of energy density and time and power parameter as the basis that exit dose calculates with acquisition.

(for example chemistry of impact point and physical attribute on by the basis of the specific interaction of the impact point of illumination; Whether use still pulsed light photograph of continuous wave (CW); The laser beam spot size; And owing to carry out laser light according to any variation of physical attribute that causes impact point with these parameters---for example absorb and scattering is enumerated in full detail, scattering anisotropy, heat conductivity, thermal capacitance and mechanical strength etc.), the doctor can regulate power density and time to obtain required energy density.Shown this relation in the treatment in vitro and in vivo in this example that provides.Therefore, under the situation of treatment tinea unguium, for the spot definition with 1-4cm diameter, power density values is from about 0.5W/cm ²To 5W/cm ²Variation makes its rank far below " degeneration " and " tissue is overheated " to keep safely and not damage/minimize the thermal interaction of infringement property laser-tissue.

Reciprocal relevant by this, as long as transmitted energy to tissue (carnival hat progression) by even geometric distribution, the required threshold energy density of NIMELS interaction can keep being independent of spot definition under these wavelength.By this logic, the NIMELS exit dose that calculate to produce the NIMELS effect to be reaching threshold energy density, thereby reduces the biological pollutant level.

NIMELS exit dose at the processing internal microorganism of this example is about 100 to 700 seconds 200J/cm ²-700J/cm ²These performance numbers do not reach the performance number that is associated with photo-thermal erosion or photo-thermal (laser/tissue).

The intensity distributions of the laser beam of calibration is determined by the power density of wave beam, and is defined as laser output power and input circular area (cm ²) ratio.Shown in Fig. 2 A and 2C, the irradiation mode of 1.5cm illumination point and area are 1.77cm ²Incident Gaussian beam pattern can be at 1.77cm ²Produce at least six different power density values in the illuminating area.These different power densities constantly strengthen (perhaps power concentration) from putting 1 (periphery) to putting 6 (central point) intensity on surf zone.In certain embodiments of the present invention, provide the beam modes that overcomes this constant error relevant with the conventional laser beam transmission.Fig. 2 B has shown that with 2D the homogeneous energy distribution of using (as " carnival hat " pattern of describing hereinafter) is to obtain more consistent power energy value in the light area in certain embodiments of the invention.

The NIMELS laser instrument is corrected this error by shining according to even pattern (carnival hat) on extended area, thereby guarantee not have or the distributed in three dimensions pattern of minimization of energy in " cold spot " or " focus ", these " cold spots " or " focus " may produce negative interference or place outside at the optical spot centre tissue of burn and to treatment have inferior treatment energy density.

In replaceable embodiment, the NIMELS parameter can be calculated by following function according to treatment time (Tn): Tn=energy density/power density.

(for example with reference to experiment in vitro) in certain embodiments in this example, Tn is about 50 to 300 seconds; In other embodiments, Tn is about 75 to 200 seconds; In other embodiment, Tn is about 100 to 150 seconds.Among the embodiment, Tn is about 100 to 450 seconds in other bodies.

Utilize above-mentioned relation and flat-top described here irradiation geometric mode, experimental results show that a series of energy i (in vivo) parameters are effective in the interior therapeutic of removing NIMELS microbial contamination.The fixed laser output that has shown the laser energy of NIMELS treatment below is 3 watts.Therefore the key parameter of given impact point is the required energy density of NIMELS treatment under various different spot definitions and the power density.

Therefore, " NIMELS exit dose " comprises from first threshold point (can optics according to target wavelength of the present invention under this point reducing the biological pollutant level the impact point) to second terminal point power density and/or the energy density scope of (will detect the healthy biological Downside Risk or the effect that can not tolerate on partly immediately before this point, for example the hot injury).It will be understood by those skilled in the art that in some cases some counter productive on the impact point (for example mammalian cell, tissue or organ) and/or risk can be under the situations of considering the inherent advantage that method of the present invention is brought and be accepted.Therefore, described terminal point is counter productive highly significant and time point when unacceptable (for example cell death, protein denaturation, DNA damage, morbidity or dead).

In certain embodiments, the power density scope is about 0.25 to about 40W/cm ²In other embodiments, the power density scope is about 0.5W/cm ²To about 25W/cm ²

In further embodiment, the power density scope comprises from about 0.5W/cm ²To about 10W/cm ²Value.Power density in this example is from 0.5W/cm ²To about 5W/cm ²

Empirical data shows, uses higher power density values when handling biological pollutant in external setting (for example culture dish) rather than body (for example toenail) usually.

(the outer example of reference body) in certain embodiments, the energy density scope is greater than 50J/cm ²But less than about 25000J/cm ²In other embodiments, the energy density scope is about 750J/cm ²To about 7000J/cm ²In other embodiments, the energy density scope is about 1500J/cm ²To about 6000J/cm ², it depends on pending biological pollutant will still be (for example toenail) targeting in the body in external background (for example culture dish).

(example in the reference body) in certain embodiments, energy density is about 100J/cm ²To about 500J/cm ²In the embodiment, energy density is about 175J/cm in other bodies ²To about 300J/cm ²In other embodiment, energy density is about 200J/cm ²To about 250J/cm ²In certain embodiments, energy density is about 300J/cm ²To about 700J/cm ²In certain other embodiments, energy density is about 300J/cm ²To about 500J/cm ²In other embodiment, energy density is about 300J/cm ²To about 450J/cm ²

The power density of the experience test of the various external treatments of microbial species is about 100W/cm ²To about 500W/cm ²

It will be appreciated by those skilled in the art that, can empirical finish by normal experiment in described power density and energy density scope, discerning optimal NIMELS radiation value for stable condition, even only finish by repetition test, because this carries out in some current available laser is used.Use the near-ir energy can be in conjunction with the doctor (for example dentist) of periodontal treatment and conventional power density and the energy density (for example according to the function of tissue color, organizational structure and the poisoning intrusion degree of depth and adjusting parameter) of regulating based on each given patient's requirement.As example, the laser therapy of the periodontal infection in the light color tissue (for example short of melanin patient) will have than the darker bigger hot security parameter of organizing, because darker tissue can more effectively absorb near-ir energy, therefore in tissue, faster these near-ir energy are converted to heat.Therefore, need the doctor to have various therapeutic schemes are discerned the ability that a plurality of different NIMELS radiate value.

As what use in this manual, singulative " a kind of " also comprises most forms of the term that it is represented, unless specify in the text.For example, " a kind of NIMELS wavelength " comprises any wavelength in the described NIMELS wave-length coverage, and the combination of these wavelength.

As used herein, unless stated otherwise, " perhaps " expression " and/or " " comprising " meaning, rather than " exclusive " meaning of " perhaps/or ".

Term " approximately " be used herein to approximate representation the zone in, roughly or near.When term " approximately " used in conjunction with digital scope, it revised this scope by the up-and-down boundary that prolongs given digital value.Common, the difference that term " approximately " is used herein to the up-and-down boundary of revising given digital value is 20%.

As what use in this manual, no matter be at the transition phrase or in claims, term " comprises " and should be understood to have inclusive sense.That is to say that this term should be understood to be synonymous to that phrase " has " at least or " comprising at least ".When using in the context of program or method, term " comprises " that the described program/method of expression comprises the step of being quoted from least, and can comprise other steps.

Can utilize and well known to a person skilled in the art that any suitable material and/or method are to carry out the present invention.Yet this paper has only described preferred material and method.The material of institute's reference, reactant or the like can obtain by commercial source in description hereinafter and the example, unless dated especially.

In aspect the 3rd, the invention provides treatment radiating system (being the NIMELS system).Fig. 2 has shown the sketch map of treatment radiation therapy apparatus in accordance with a preferred embodiment of the present invention.Therapy system 10 comprises that optical radiation generates equipment 12, transfer device 14, application apparatus (perhaps zone) 16, and controller 18.According to an aspect of the present invention, described light radiation is a laser.In certain embodiments, transfer device 14 produces " flat-top " Energy distribution with uniform distribution energy on very big zone.Optical radiation production equipment 12 comprises laser oscillator 26 and 28, a laser oscillator 26 is configured to transmitting optics radiation in first wave-length coverage of 850nm to 900nm, and another laser oscillator 28 is configured to emitted radiation in second wave-length coverage of 905nm to 945nm.In certain embodiments, a laser oscillator is configured to transmitting optics radiation in first wave-length coverage of 865nm to 875nm, and another laser oscillator 28 is configured to emitted radiation in second wave-length coverage of 925nm to 935nm.Transfer device 14 preferably comprises the flexible optical fibre of prolongation, and the dual wavelength radiation delivery that is suitable for the device of self-oscillation in the future 26 and 28 is to application apparatus 16.Application apparatus 16 can have multi-form (for example comprising that safety device is to prevent heat injury) based on application demand.For example, in one form, application apparatus 16 can be configured to have minimum dimension and have the shape that can insert patient body.In a kind of replaceable form, application apparatus 16 can be configured to have the mode that cone shape disperses with taper shape and carry out radiation, thereby radiation is applied to relatively large zone.Demand based on point of application can adopt the application apparatus 16 with other size and dimensions.

In a preferred embodiment, controller 18 comprises the load limiter 24 that is connected to laser oscillator 20 and 22, it is used to control the radiation dose by application apparatus 16 transmission, thereby the time integral of the radiating power density of each unit are transmission is lower than predetermined threshold, and described predetermined threshold is set to prevent the corresponding damage of using the health tissues of point.Controller 18 may further include memorizer 26, is used for the treatment information of store patient.The stored information of particular patient can include but not limited to radiation dose (for example comprising which wavelength, power density, treatment time, skin pigment deposition parameter or the like) and point of application information (for example comprising point of care type (wound, cancer etc.), size, degree of depth or the like).In a preferred embodiment, memorizer 26 can also be used to store dissimilar disease informations and with the treatment archives of particular type disease association, for example radiation mode and radiation dose.Controller 18 may further include exit dose and calculates device 28, is used for being imported the point of application information of controller and being calculated the required dosage of particular patient by the doctor based on application type and other.In one form, controller 18 further comprises imaging system, is used for point of application is carried out imaging.Described imaging system is calculated device 28 to carry out Rapid Dose Calculation based on the image collection point of application information of point of application and with the information transmission of collecting to exit dose.The information that the doctor also can manually compute and import by image collection arrives controller 18.

As shown in Figure 2, controller may further include control panel 30, and the doctor can manually control therapy system by described control panel.Therapy system 10 can also be by computer control, and described computer has controlling platform, for example based on WINDOWS ^TMPlatform.Parameters such as the pulse strength of optical radiation, pulse width, pulse repetition rate can be controlled by computer and control panel 30.

Fig. 3 a-3d has shown can be from treating the different optical radiation mode of systems communicate to point of application.Optical radiation can only be transmitted according to a wave-length coverage, for example in first wave-length coverage of 850nm to 900nm, perhaps in the scope of 865nm to 875nm, perhaps in second wave-length coverage of 905nm to 945nm, perhaps in the scope of 925nm to 935nm, shown in Fig. 3 a.Radiation in the radiation in first wave-length coverage and second wave-length coverage also can generate multiplex system in the equipment 12 and carries out multiplexedly by being installed in optical radiation, and is delivered to point of application according to multiplexed form, shown in Fig. 3 b.In a kind of replaceable form, the radiation in the radiation in first wave-length coverage and second wave-length coverage can be applied to point of application simultaneously and not pass through multiplex system.Fig. 3 c has shown that optical radiation can be according to being interrupted the over-over mode transmission, for example, it at first is first pulse in first wave-length coverage, it then is second pulse in second wave-length coverage, be the 3rd pulse in first wave-length coverage afterwards once more, and be the 4th pulse in second wave-length coverage once more, by that analogy.Described interval can be CW (continuous wave), a pulse shown in Fig. 3 c, perhaps two or multiple-pulse (not shown) more.Fig. 3 d has shown another kind of pattern, and wherein point of application at first by the radiation therapy in the scope (for example first wave-length coverage) in two wave-length coverages, is treated by the radiation in another wave-length coverage then.The treatment pattern can be by the doctor based on the type of point of application and other information and determine.

Any aspect of the present invention is not determined observed restriction of arriving the mechanical theory of phenomenon, can suppose that the wavelength of the method according to this invention and systems radiate is absorbed by the lipid bilayer of giving birth in chromophore and the cell membrane in protokaryon and the eukaryotic iuntercellular.Can suppose that further the damage of possible antibacterial can alleviate by poisonous singlet oxygen and/or other reactive oxygen species.

The following examples have further been set forth some preferred embodiment of the present invention, and do not limit the scope of the invention.

Example I

The NIMELS exit dose calculates

As above described in detail, the NIMELS parameter comprises the average single of laser diode or stack output, and the wavelength of diode (870nm and 930nm).Laser beam area (the cm of this information and impact point ²) combining provides initial information, described initial information can be used to calculate according to effective and safe radiation scheme of the present invention.

The power density of given laser has been weighed the potential effect of the NIMELS of impact point.Power density is the function of any given laser output power and beam area, and can calculate according to following equation:

For single wavelength:

1) power density (W/cm ²)= Laser output power

Beam diameter (cm ²)

Treat for dual wavelength:

Beam area can followingly calculate:

3) beam area (cm ²)=diameter (cm) ²* 0.7854 or beam area (cm ²)=Pi* radius (cm) ²

Measure by joule to the total light energy in the tissue by a NIMELS laser diode systems communicate of in some cycles, under specific output, working, and following calculating:

4) gross energy (joule)=laser output power (watt) * time (second)

Measure by joule by total light energy that two NIMELS laser diode systems (two wavelength) of working under specific output in some cycles are delivered in the tissue simultaneously, and following calculating:

5) gross energy (joule)=[laser (1) output (watt) * time (second)]+[laser (2) output (watt) * time (second)]

In force, know gross energy on the radiation therapy zone distribution and distribute very useful (but inessential), thereby can right metric dosage with maximization NIMELS advantage.Gross energy distributes can pass through energy density (joule/cm ²) tolerance.As described hereinafter, for the setted wavelength light beam, energy density is most important factor for definite tissue reaction.The energy density of a NIMELS wavelength can followingly be derived:

7) energy density (joule/cm ²)=power density (W/cm ²) the * time (second)

When using two NIMELS wavelength, energy density can followingly be derived:

9) energy density (joule/cm ²)=power density (1) (W/cm ²) the * time (second)+power density (2) (W/cm ²) the * time (second)

In order to calculate the treatment time of given dose, the user can use energy density (J/cm ²) or energy (J), and output (W) and beam area (cm ²), use one in the following equation to calculate:

10) treatment time (second)=energy density (J/cm ²)/output power density (W/cm ²)

11) treatment time (second)=energy (J)/laser output power (W)

Because exit dose calculates (for example being given an example in this example) may be very heavy, therapy system also can comprise Computer Database, stores treatment probability and exit dose that all were studied.Computer in the controller (exit dose and parameter calculator) carries out pre-programmed by the algorithm based on above-mentioned formula, thereby any operator is extraction data and parameter on screen easily, and import additional necessary data (for example the time of spot definition, required gross energy, each wavelength and pulse width, by radiating tissue, by radiating antibacterial) and any other necessary information, thereby realize that any and all algorithms of optimum therapeuticing effect and calculating can produce by exit dose and parameter calculator, and start laser thus.

Example II

Antibacterial method: the NIMELS treatment parameter of external escherichia coli targeting

Below example of parameters be applied to colibacillary method according to of the present invention, wherein final temperature is far below the temperature that causes the hot injury in this area.

A. the experiment material of e. coli k-12 and method:

The e. coli k12 fluid medium is grown in Luria Bertani (LB) culture fluid (25g/L).Culture dish comprises the LB culture fluid (25g/L LB, 15g/L bacteria Agr) of 35mL.Use phosphate buffered saline (PBS) (PBS) that culture medium is diluted.All schemes and operation all use aseptic technique to carry out.

B. growth kinetics

Inoculated and growth under 37 ℃ from a plurality of 50mL LB culture medium of seed culture medium deposits yields.Second day morning, select the most healthy culture and be used for inoculation 5% to 50mLLB and monitoring O.D.600 under 37 ℃, promptly measured every 30 to 45 minutes, be in resting stage up to culture.

C. original seed production

From logarithmic (log) phase culture (O.D.600 is approximately 0.75), 10mL is placed under 4 ℃.Add 50% glycerol of 10mL and its branch is installed in 20 ice chests, and quick-freezing in liquid nitrogen.Then ice chest is stored under-80 ℃.

D. liquid culture

The foregoing structure of the liquid culture of e. coli k12.From subculture, take out component and the serial dilution to 1 in PBS of 100 μ L: 1200.This diluent can at room temperature be cultivated about two hours or further increase up to not observing O.D.600, thereby guarantee that the cell in the PBS suspension reaches static (growth aspect) and do not have remarkable division, and can extract phase further be tested by the cell of constant number.

Be in static state in case determine the K12 diluent, this suspension of 2mL is extracted the NIMELS experiment of selected culture dish to select in 24 tissue culture's wares under given exit dose parameter.Described culture dish is at room temperature cultivated up to using (about 2 hours).

After laser treatment, from each culture dish, take out 100 μ l and serial dilutions to 1: 1000, produce 1: 12 * 105 final diluent of initial K12 culture.3 * 200L component of each final diluent in triplicate by separate application to independent culture dish.Described then culture dish was cultivated about 16 hours down at 37 ℃.Carry out artificial colony counting and record.Take the digital photos of each culture dish simultaneously.

Identical cell growth and kinetics scheme are adopted in NIMELS radiation experiment to all staphylococcus aureuses and Candida albicans testing in vitro.

Begin PBS solution is carried out the heat test from room temperature.Before system temperature is elevated near 44 ℃ threshold limit value, can use 10 watts NIMELS laser energy in the cycle at 12 minutes laser.

Table II: the time-temperature of external NIMELS exit dose is measured

NIMEL output (W)	Wave beam luminous point 1.5cm diameter overlapping region (cm2)	Treatment time (Sec)	Gross energy (joule)	Energy density (radioactive exposure) (J/cm2)	Power density (radiation) (W/cm2)	Initial temperature	Final temperature
NIMEL output (W)		Treatment time (Sec)	Gross energy (joule)	Energy density (radioactive exposure) (J/cm2)	Power density (radiation) (W/cm2)	Initial temperature	Final temperature	Culture dish 1-N--3.0+3.0=6.0W	1.76	720	4320	2448	3.40	20.5℃	34.0℃
Culture dish 2-N--3.5+3.5=7.0W	1.76	720	5040	2858	3.97	20.7℃	36.5℃	Culture dish 1-N--3.0+3.0=6.0W	1.76	720	4320	2448	3.40	20.5℃	34.0℃
Culture dish 2-N--3.5+3.5=7.0W	1.76	720	5040	2858	3.97	20.7℃	36.5℃	Culture dish 3-N-4.0+4.0=8.0W	1.76	720	5760	3268	4.54	21.0℃	38.5℃
Culture dish 4-N-4.5+4.5=9.0W	1.76	720	6480	3679	5.11	2.0℃	41.0℃	Culture dish 3-N-4.0+4.0=8.0W	1.76	720	5760	3268	4.54	21.0℃	38.5℃
Culture dish 4-N-4.5+4.5=9.0W	1.76	720	6480	3679	5.11	2.0℃	41.0℃	Culture dish 5-N-5.0+5.0=10.W	1.76	720	7200	4089	5.68	21.0℃	40.5℃
Culture dish 6-N-5.5+5.5=11W	1.76	720	7920	4500	6.25	21.0℃	46.0℃	Culture dish 5-N-5.0+5.0=10.W	1.76	720	7200	4089	5.68	21.0℃	40.5℃
Culture dish 6-N-5.5+5.5=11W	1.76	720	7920	4500	6.25	21.0℃	46.0℃	Culture dish 7-N-7.0+7.0=14.0W	1.76	360	5040	2863	7.95	21.0℃	47.0℃
Culture dish 8-N-7.5+7.5=15W	1.76	360	5400	3068	8.52	21.7℃	47.2℃	Culture dish 7-N-7.0+7.0=14.0W	1.76	360	5040	2863	7.95	21.0℃	47.0℃

EXAMPLE III

Radiation value in the extracorporeal treatment under the NIMELS optical maser wavelength 930nm

In following scope, the single wavelength X=930nm of NIMELS has quantifiable antibacterial effect at external escherichia coli in the safe thermal parameter to mammalian tissues.

The experiment in vitro data show, if to import the gross energy of independent 930nm system be 5400J and satisfy 3056J/cm in 25% following time ²Energy density, still reached 100% bactericidal effect.

Table III: the external escherichia coli targeting hot NIMELS in the Central Asia (λ=930) exit dose

Output (W)	Wave beam luminous point (CW)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Escherichia coli kill percentage ratio
Output (W)	Wave beam luminous point (CW)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Escherichia coli kill percentage ratio	7.0	1.5	720	5040	2852	3.96	40.2％
8.0	1.5	720	5760	3259	4.53	100.0％	7.0	1.5	720	5040	2852	3.96	40.2％
8.0	1.5	720	5760	3259	4.53	100.0％	10.0	1.5	540	5400	3056	5.66	100.0％

The experiment in vitro data show that in following scope, the energy of single wavelength X=930nm has antibacterial effect (in the safe thermal parameter to mammalian tissues) at external staphylococcus aureus.

Can believe simultaneously, for staphylococcus aureus and other antibacterials, if the gross energy of input system is 5400J and satisfies 3056J/cm in 25% following time ²Energy density, still can reach 100% bactericidal effect.

Table IV: the external staphylococcus aureus targeting hot NIMELS in the Central Asia (λ=930) exit dose

Output (W)	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Staphylococcus aureus kills percentage ratio
Output (W)	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Staphylococcus aureus kills percentage ratio	7.0	1.5	720	5040	2852	3.96	24.1％
8.0	1.5	720	5760	3259	4.53	100.0％	7.0	1.5	720	5040	2852	3.96	24.1％

The experiment in vitro data show that the single wavelength X=930nm of NIMELS has anti-mycotic efficiency at external fungus (and opportunistic human body pathogen) Candida albicans in the safe thermal parameter to mammalian tissues.

Can believe simultaneously, for staphylococcus aureus and other antibacterials, if the gross energy of input system is 5400J and satisfies 3056J/cm in 25% following time ²Energy density, still can reach 100% anti-mycotic efficiency.With reference to figure 3.

Table V: low grade fever NIMELS (λ=930) exit dose during external Candida albicans is handled

Output (W)	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Candida albicans kills percentage ratio
Output (W)	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Candida albicans kills percentage ratio	8.0	1.5	720	5760	3259	4.53	100.0％
9.0	1.5	720	6840	3681	5.11	100.0％	8.0	1.5	720	5760	3259	4.53	100.0％

EXAMPLE IV

The radiation value of external NIMELS optical maser wavelength 870nm

The experiment in vitro data show, under single wavelength of 870nm up to gross energy and the 4074J/cm of 7200J ²Energy density and 5.660W/cm ²Power density under significantly do not kill effect at escherichia coli.

Table VI: escherichia coli research---single wavelength X=870nm

Output (W)	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Control CFU	NIMELS CFU	Difference control--NIMEL	Escherichia coli kill percentage ratio
Output (W)	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Control CFU	NIMELS CFU	Difference control--NIMEL	Escherichia coli kill percentage ratio	6.0	1.5	720	4320	2445	3.40	90	95	(5)	-5.6％
7.0	1.5	720	5040	2852	3.96	94	94	0	0.0％	6.0	1.5	720	4320	2445	3.40	90	95	(5)	-5.6％
7.0	1.5	720	5040	2852	3.96	94	94	0	0.0％	8.0	1.5	720	5760	3259	4.53	93	118	(25)	-26.9％
9.0	1.5	720	6480	3667	5.09	113	112	1	0.9％	8.0	1.5	720	5760	3259	4.53	93	118	(25)	-26.9％
9.0	1.5	720	6480	3667	5.09	113	112	1	0.9％	10.0	1.5	720	7200	4074	5.66	103	111	(8)	-7.8％
10.0	1.5	540	5400	3056	5.66	120	101	19	15.8％	10.0	1.5	720	7200	4074	5.66	103	111	(8)	-7.8％

Use the radiation of single wavelength X=870nm also to observe analog result at staphylococcus aureus.

EXAMPLE V

The unique alternately synergy of NIMELS between 870nm and the 930nm optical energy

The experiment in vitro data show, when two NIMELS wavelength (λ=870nm and 930nm) replace (870nm is before 930nm), have synergistic effect between two NIMELS wavelength.The 870nmNIMELS wavelength has definitely strengthened the antibacterial effect of second 930nm NIMELS wavelength radiation as first radiation.

The experiment in vitro data show, when wavelength makes up according to over-over mode (870nm is before 930nm), this synergy (combination 870nm wavelength and 930nm wavelength) allows the optical energy of 930nm to be reduced to about 1/3 of NIMELS required gross energy of 100% escherichia coli antibacterial effect and energy density.

The experiment in vitro data also show, 870nm optical energy as isodose was added to system with 20% higher power density before the 930nm energy, this synergistic mechanism allows 930nm optical energy (gross energy and energy density) to be reduced to about 1/2 of the required total energy density of NIMELS 100% escherichia coli antibacterial effect.

Table VII: adopt the escherichia coli data when replacing the NIMELS wavelength

Output (W)	Luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Escherichia coli kill percentage ratio
Output (W)	Luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Escherichia coli kill percentage ratio	8W/ 8W	1.5	540/180 12min.	4320/1440 ＝5760	2445/815 ＝3529	4.53/4.53	100.0％
10W/ 10W	1.5	240/240 8min.	2400/2400 ＝4800	1358/1358 ＝2716	5.66/5.66	100.0％	8W/ 8W	1.5	540/180 12min.	4320/1440 ＝5760	2445/815 ＝3529	4.53/4.53	100.0％

This cooperative ability is extremely important for tissue safety, because the 930nm optical energy can be with the faster speed heating system than 870nm optical energy, and is favourable for mammlian system, because can produce the least possible heat in treatment.

Can believe simultaneously, if NIMELS optical energy (870nm and 930nm) can reach 100% antibacterial effect equally substantially at the radiation that hockets in the manner described above of other antibacterials.

The experiment in vitro data show that also two NIMELS wavelength (870nm and 930nm) replace under the situation of (870nm is before the 930nm) when the radiation fungus, also have synergistic effect between two NIMELS wavelength.The NIMELS wavelength of 870nm is as the anti-mycotic efficiency of the NIMELS wavelength radiation that has strengthened second 930nm on the first radiation mathematics.

The experiment in vitro data show (with reference to following table), 870nm optical energy as isodose was added to system with the power density of the power density more required than sterilization effect high 20% before the 930nm energy, this synergistic mechanism allows 930nm optical energy (gross energy and energy density) to be reduced to about 1/2 of the required total energy density of NIMELS100% escherichia coli antibacterial effect.

Table VII: utilize the alternately data of NIMEL wavelength radiation Candida albicans

Output (W)	Luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Candida albicans kills percentage ratio
Output (W)	Luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Candida albicans kills percentage ratio	10W/ 10W	1.5	240/240 8min	2400/2400 ＝4800	1358/1358 ＝2716	5.66/5.66	100.0％ ^＊

Can believe simultaneously,, can reach 100% anti-mycotic efficiency substantially equally if NIMELS optical energy (870nm and 930nm) replaces radiation in the manner described above at other funguses.

Example VI

The unique synergy simultaneously of NIMELS between λ=870nm and the 930nm optical energy

The experiment in vitro data show, when two NIMELS wavelength (870nm and 930nm) when using simultaneously (870nm is in conjunction with 930nm), have synergistic effect between two NIMELS wavelength.870nmNIMELS and 930nm NIMELS wavelength carry out the antibacterial effect that the absolutization of radiation has simultaneously strengthened the NIMELS system.

The experiment in vitro data show (for example with reference to down Table VIII and IX), and required gross energy and energy density is only about half of when effectively 930nm optical energy and density being reduced to single treatment used according to the invention by combination λ=870nm and λ=930nm (using simultaneously in this example).

Table VIII: utilize the colibacillary data of combination NIMEL wavelength radiation

Output (W) 870NM/ 930NM	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Escherichia coli kill percentage ratio
Output (W) 870NM/ 930NM	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Escherichia coli kill percentage ratio	5W+5W＝10	1.5	720	3600(×2) ＝7200	2037(×2) ＝4074	5.66	100％

Table I X: the data of utilizing combination NIMEL wavelength radiation staphylococcus aureus

Output (W) 870NM/ 930NM	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	The Portugal coccus kills percentage ratio in golden yellow Portugal
Output (W) 870NM/ 930NM	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)		5W+5W＝10 W	1.5	720	3600(×2) ＝7200	2037(×2) ＝4074	5.66	98.5％
5.5W+5.5＝11 W	1.5	720	3960(×2) ＝7920	2241(×2) ＝4482	6.22	100％	5W+5W＝10 W	1.5	720	3600(×2) ＝7200	2037(×2) ＝4074	5.66	98.5％

This while cooperative ability is extremely important for tissue safety, because the 930nm optical energy can be with the faster speed heating system than 870nm optical energy, and for mammlian system is favourable, because can produce the least possible heat in treatment.

Can believe simultaneously,, can reach 100% anti-mycotic efficiency substantially equally if NIMELS optical energy (870nm and 930nm) is used in the manner described above simultaneously at other bacterial communities.With reference to figure 4 and Fig. 5.

The experiment in vitro data also show, when two NIMELS wavelength (870nm and 930nm) use simultaneously on fungus, have synergistic effect between two NIMELS wavelength.The NIMELS wavelength of 870nm and the NIMELS wavelength of 930nm carry out the anti-mycotic efficiency that radiation has simultaneously definitely strengthened the NIMELS system.

The experiment in vitro data show (reference table), when two wavelength were combined according to concurrent mode, this cooperative effect (the 870nm wavelength is attached to the 930nm wavelength carries out radiation simultaneously) allowed the optical energy of 930nm to be reduced to about 1/2 of required gross energy of NIMELS 100% Candida albicans anti-mycotic efficiency and energy density.

Table X: the Candida albicans data of combination NIMEL wavelength

Output (W) 870NM/ 930NM	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Candida albicans kills percentage ratio
Output (W) 870NM/ 930NM	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Candida albicans kills percentage ratio	5W+5W＝10	1.5	720	3600(×2)＝ 7200	2037(×2)＝4074	5.66	100％

Utilizing and during luminous energy that exploitation is unique, NIMELS wavelength (870nm and 930nm) is used for alternating treatment and/or treats simultaneously that for example the integrity of mammiferous tissue is extremely important for maintenance with the ability that realizes 100% antibiotic and 100% anti-mycotic efficiency (depending on the situation and the pathology that relate to).Verified, the 930nm optical energy than 870nm optical energy with the faster speed heating system, and it to produce the least possible heat for mammlian system during antibacterium and antifungal therapy be favourable.

When utilizing and developing the NIMELS cooperative effect, NIMELS wavelength (870nm and 930nm) is used for independent treatment, alternating treatment and/or treatment (depending on the situation and the pathology that relate to) simultaneously to realize that 100% antibacterial effect is unique and novel for the NIMELS system.

The experiment in vitro data also show, when escherichia coli carry out radiation by control wavelength 830nm separately according to following parameter (reference table), 830nm control laser produces zero antibacterial effect in 12 minutes radiation period, 930nm has reached 100% antibiotic and anti-mycotic efficiency with minimum NIMELS exit dose under identical parameters.

Table X I: the single wavelength 830nm of escherichia coli

Output (W)	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)
Output (W)	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	8.0	1.5	720	5760	3259	4.53
9.0	1.5	720	6480	3667	5.09	8.0	1.5	720	5760	3259	4.53
9.0	1.5	720	6480	3667	5.09

The experiment in vitro data also show, when under the safe exit dose of heat, applying, when 830nm wavelength and NIMELS 930nm wavelength by alternately the time, do not have synergistic effect between the two.830nm control wavelength is producing effect aspect the Synergistic antimicrobial effect far below the NIMELS wavelength of 870nm as first radiation with the 2nd 930nm NIMELS wavelength.

Table X II: replace with the alternately colibacillary data of property 830nm control wavelength radiation

Output (W) 830NM/ 930NM	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Escherichia coli kill percentage ratio
Output (W) 830NM/ 930NM	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Escherichia coli kill percentage ratio	8W/8W	1.5	540/180 12min	4320/1440＝5760	2445/815＝3529	4.53/4.53	0％
10W/10W	1.5	240/240 8min	2400/2400＝4800	1358/1358＝2716	5.66/5.66	65％	8W/8W	1.5	540/180 12min	4320/1440＝5760	2445/815＝3529	4.53/4.53	0％

The experiment in vitro data also show when applying, to have lower synergistic effect when using 830nm ripple product and 930nm wavelength simultaneously under the safe exit dose of heat.In fact, the experiment in vitro data show, compare with the combination of 930nm with the available 830nm of commerce, reach 100% the required gross energy of escherichia coli antibacterial effect low 17% when 870nm and 930nm make up simultaneously, energy density is low by 17%, and power density low 17%.This greatly reduce equally by NIMELS wavelength when treatment to body in the hot injury of system.

Table X III: the escherichia coli data that replace with concurrent 830nm control wavelength

Output (W) 830NM/ 930NM	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Escherichia coli kill percentage ratio
Output (W) 830NM/ 930NM	Wave beam luminous point (CM)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	Escherichia coli kill percentage ratio	5W+5W＝10	1.5	720	3600(×2) ＝7200	2037(×2)＝4074	5.66	91％
5.5W+5.5 ＝11W	1.5	720	3960(×2) ＝7920	2250(×2)＝4500	6.25	90％	5W+5W＝10	1.5	720	3600(×2) ＝7200	2037(×2)＝4074	5.66	91％
5.5W+5.5 ＝11W	1.5	720	3960(×2) ＝7920	2250(×2)＝4500	6.25	90％	6W+6W ＝12W	1.5	720	3960(×2) f ＝8640 ^＊	2454(×2) ＝4909 ^＊	6.81 ^＊	100％

The antibacterial amount of killing

The experiment in vitro data show that also external NIMELS laser system is for comprising 2000000 (2 * 10 ⁶) escherichia coli of colony forming unit (CFU) and the bacterial solution of staphylococcus aureus 100% success (in hot tolerance range).This has increased twice with respect to common being seen situation in the infected human chronic ulcer tissue sample of 1gm.People such as Brown have reported that the microbial cell in 75% the diabetics all is at least 100000CFU/gm, and in 37.5% patient, the amount of microbial cell is greater than 1000000 (1 * 10 ⁶) CFU (with reference to Brown et al., Ostomy WoundManagement, 401:47, issue 10,2001).

Thermal parameter:

The vitro data data show that the NIMELS laser system can realize 100% antibacterium and anti-mycotic efficiency in the hot safety range of tissue.With reference to figure 6.

Example VII A

More low temperature is to the effect of NIMELS

Dewhirst et al., Internat.J.of Hyperthermia, 19 (3): 267-294 has reported that more low temperature is to the effect of antibacterial.

The cooling of antibacterial:

The experiment in vitro data show, by in PBS the initial temperature of bacteria sample being changed to 4 ℃ of maintenances two hours at laser before the cycle, all can not realize the optics antibacterial effect by the NIMELS laser system with any present issuable antimicrobial energy.

Most probable explanation is can not produce or produce few oxygen-derived free radicals under the metabolic situation that bacterial cell is in " metabolism stagnation " and generation does not enliven in cell.This is that the binding mode of proof NIMELS laser aid is the another data point that attack bacteria is breathed center and cell membrane.

(but not being used) mechanism of inferring is that the energy of 870nm influences cytochrome by the accelerated oxidation phosphorylation, and the 930nm energy destroys cell membrane and thus by producing singlet oxygen with electric transmission system uncoupling, and does not allow terminal O ₂Molecule is reduced.

Example VII A I

TRYCHOPHYTONRUBRUM

Table X IV: the alternately NIMELS Trichophyton of wavelength test

The experiment sequence number	Output (W) 870NM/ 930NM	Wave beam luminous point (cm)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)
The experiment sequence number	Output (W) 870NM/ 930NM	Wave beam luminous point (cm)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	1	8W/8W	1.5	540/180 12min.	4320/1440 ＝5760	2445/815 ＝3529	4.53/4.53
2	10W/10W	1.5	240/240 8min.	2400/2400 ＝4800	1358/1358 ＝2716	5.66/5.66	1	8W/8W	1.5	540/180 12min.	4320/1440 ＝5760	2445/815 ＝3529	4.53/4.53

The minimum effect of experiment No.1=

100% kills in all culture dishs of experiment No.2=

Table X V:NIMELS Trichophyton---while wavelength

The experiment sequence number	Output (W) Λ=870 NM﹠ Λ=930 NM	Wave beam luminous point (cm)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)
The experiment sequence number	Output (W) Λ=870 NM﹠ Λ=930 NM	Wave beam luminous point (cm)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	3	5+5＝10	1.5	720 12min.	3600(×2)＝7200	2037(×2)＝4074	5.66
4	5.5W+5.5W ＝11W	1.5	720	3960(×2)＝7920	2250(×2)＝4500	6.25	3	5+5＝10	1.5	720 12min.	3600(×2)＝7200	2037(×2)＝4074	5.66
4	5.5W+5.5W ＝11W	1.5	720	3960(×2)＝7920	2250(×2)＝4500	6.25	5	6W+6W ＝12W	1.5	720	3960(×2)＝8640	2454(×2)＝4909	6.81

Experiment No.3,4,100% kills in all culture dishs of 5=

Table X VI:NIMELS Trichophyton---single wavelength

Experiment sequence number λ=930	Output (W)	Wave beam luminous point (cm)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)
Experiment sequence number λ=930	Output (W)	Wave beam luminous point (cm)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	6	8.0	1.5		5760	3259	4.53

			720
			720				7	9.0	1.5	720	6840	3681	5.11

Experiment No.6,100% kills in all culture dishs of 7=

Table X VII: control Trichophyton---830nm/930nm alternately

Experiment sequence number λ 830﹠ λ=930	Output (W)	Wave beam luminous point (cm)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)
Experiment sequence number λ 830﹠ λ=930	Output (W)	Wave beam luminous point (cm)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	8	8W/8W	1.5	540/180 12min	4320/1440＝5760	2445/815＝3529	4.53/4.53
9	10W/10W	1.5	240/240 8min	2400/2400＝4800	1358/1358＝2716	5.66/5.66	8	8W/8W	1.5	540/180 12min	4320/1440＝5760	2445/815＝3529	4.53/4.53

Experiment No.8=does not have effect

Experiment No.9=100% kills

Table X VIII: use λ=830nm and 930nm to handle external Trichophyton

Output (W)	Wave beam luminous point (cm)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)
Output (W)	Wave beam luminous point (cm)	Time (second)	Gross energy (joule)	Energy density (J/CM ²)	Power density (W/CM ²)	5+5＝10	1.5	720	3600(×2) ＝7200	2037(×2)＝4074	5.66

As above the treatment of describing among the Table X VIII causes 100% to kill.

Example I X

Tinea unguium treatment evaluation and test

This example has shown how the doctor evaluates and tests treatment and determine whether to increase, reduce or continue particular treatment dosage, radiation mode in evaluation and test.With reference to figure 8, healthy deck is hard and translucent, and is made up of dead keratin.The deck is surrounded by perionychium, and perionychium is made up of the zone of near-end and side direction fingernail fold, hyponychium and fingernail free edge below.Fig. 9 has shown typical tinea unguium patient's fingernail diagram, by representing the effectiveness that healthy nail growth has confirmed treatment.Clean and " uninfection " that the doctor should be appreciated that newborn deck partly (near primary parent, eponychium and lunula of nail) need not carry out radiation in successive treatment.Therefore, radiant should aim at the affected areas that still has pathogen.

In some examples, be subjected to fingernail " thicker " (because malnutrition growth) that tinea unguium infects or " painted " (because colourity that mycovirus produces) (with reference to Figure 10) and may need the longer laser emission time (higher energy density) to arrive the infected area (no Rhizoma Anemarrhenae's body and primary parent) of nail matrix and the fingernail fold lunula of nail that below eponychium, grows to penetrate the deck.

As shown in figure 11, in patient with concurrent chronic paronychia, " spot definition " in laser therapy zone should be extended covering infected paronychia zone, thereby the NIMELS laser therapy can be passed through in the viral infection zone of guaranteeing all fingernail complexs.

In some cases, tinea unguium patient may have by the different dispersion fingernail zone of viral infection, the healthy part still hard and translucent (with reference to Figure 11) in other clean fully regional middle decks.This can and can arrive and exceed the lunula of nail that grows below eponychium for vertical or horizontal pattern.In these cases, the doctor is appreciated that clean and " uninfection " part on deck does not need by radiation, and spot definition and laser radiation amount should corresponding adjusting can not damaged any part of healthy fingernail complex successfully to treat.And if the geometry of the infected part of fingernail can not simply be passed through " less luminous point " and fully treated, healthy fingernail part can be by covering with the bigger laser emission point of permission with opaque material.

Embodiment X

The combination laser output is fixed on the reciprocal relevant progression of 3.0 watts the interior NIMELS treatment of body

Analyze (reciprocal progression analysis): 870NM and 930NM are 1.5W

In order to be presented at the canonical analysis of carrying out in the interior therapeutic, following example supposition uses output as the laser of 3W to pass through λ=870 and 930nm emitted energy.

Table X IX: dual wavelength λ=870 and 930nm

In the case, Tn=409 (energy density)/power density.Figure 14 has shown the derived value of given spot definition (1.2-2.2cm diameter).The treatment time of NIMELS treatment be by under 3.0 watts laser output power with 409J/cm ²Energy density draw divided by power density.

Example XI

Laser output power is fixed on NIMELS treatment in the body that 3.0 watts and wavelength are 930NM Reciprocal relevant progression analysis

In order to be presented at the canonical analysis of carrying out in the interior therapeutic, following example supposition uses output as the laser of 3W to pass through λ=930nm emitted energy.

Table X X: single wavelength X=930nm

On the basis of the data that observed (table data in the reference), we find Tn=205 (energy density)/power density.Therefore, in given spot definition parameter (1.2-2.2cm diameter) scope, the treatment time of NIMELS treatment can simply pass through under 3.0 watts laser output power 205J/cm ²Energy density draw (with reference to Figure 13) divided by power density.

The new algorithm that this NIMELS exit dose calculates relates to based on (λ=870nm and 930nm are together) simultaneously or the known and constant NIMELS threshold energy density of using the unique wavelength of the energy delivery of 930nm wavelength to come quantitative antibacterium environment separately.

Therefore, in the treatment of NIMELS antibacterium, this (energy density) quantization method can be saved and use the updating value of the NIMELS factor (Tn) with the reciprocal relevant association of the parabolic type of necessity of computationally secure and efficient emission value.

This of short duration and reciprocal relevant exit dose NIMEL method should be suitable for different laser output power (1W-5W), and condition is that any quantifiable heat in the tissue increases, continue hot rise time and biochemical reaction is maintained under any irreversible damage threshold.

Claims

1. one kind is reduced the biological pollutant level of impact point and can partly not produce the method for the negative effect that can not tolerate to biology, may further comprise the steps: by having from about 905nm to the about optical radiation of 945nm wavelength impact point is carried out radiation under the NIMELS exit dose.

2. one kind is reduced the biological pollutant level of impact point and can partly not produce the method for the negative effect that can not tolerate to biology, may further comprise the steps: by having from about 925nm to the about optical radiation of 935nm wavelength impact point is carried out radiation under the NIMELS exit dose.

3. a biological pollutant level that reduces impact point and the method that can partly not have a negative impact to biology may further comprise the steps:

(a) under the NIMELS exit dose, impact point is carried out radiation by having from the optical radiation of about 850nm to 900nm wavelength; And

(b) by having impact point is carried out radiation from second optical radiation of about 905nm to 950nm wavelength.

4. a biological pollutant level that reduces impact point and the method that can partly not have a negative impact to biology may further comprise the steps:

(a) under the NIMELS exit dose, impact point is carried out radiation by having from the optical radiation of about 865nm to 875nm wavelength; And

(b) by having impact point is carried out radiation from second optical radiation of about 925nm to 935nm wavelength.

5. according to any one described method in the claim 1 to 4, wherein said biological pollutant is selected from the group of being made up of antibacterial, fungus, mycete, mycoplasma, protozoacide, Protein virus, parasite and virus.

6. according to any one described method in the claim 1 to 4, wherein said biological pollutant is selected from the group of being made up of Trichophyton (Trichophyton), sporidiole bacteria (Microsporum), epidermophyton (Epidermophyton), candidiasis (Candida), little broom sample mycete (Scopulariopsis brevicaulis), reaping hook mould (Fusarium spp.), aspergillosis (Aspergillus spp.), chain lattice bacterium (Alternaria), top spore mould (Acremonium), Scytalidinium dimidiatum and Scytalidinium hyalinum.

7. according to any one described method in the claim 1 to 4, wherein said biological pollutant is a Trichophyton.

8. according to any one described method in the claim 1 to 4, wherein said biological pollutant is escherichia coli.

9. according to any one described method in the claim 1 to 4, wherein said biological pollutant is a staphylococcus.

10. according to any one described method in the claim 1 to 4, wherein said biological pollutant is a candidiasis.

11. according to claim 3 or 4 described methods, wherein said step (a) and (b) independently carry out.

12. according to claim 3 or 4 described methods, wherein said step (a) and (b) carry out in turn.

13. according to claim 3 or 4 described methods, wherein said step (a) and (b) carry out substantially simultaneously.

14. according to any one described method in claim 1 or 2, wherein said optical radiation provided in about 50 to about 300 seconds time (Tn).

15. according to any one described method in claim 1 or 2, wherein said optical radiation provided in about 75 to about 200 seconds time (Tn).

16. according to any one described method in claim 1 or 2, wherein said optical radiation provided in about 100 to about 150 seconds time (Tn).

17. according to any one described method in claim 1 or 3, wherein said optical radiation provided in about 100 to about 450 seconds time (Tn).

18. according to any one described method in the claim 1 to 4, wherein said NIMELS exit dose provides from about 100J/cm ²To about 500J/cm ²Energy density.

19. according to any one described method in the claim 1 to 4, wherein said NIMELS exit dose provides from about 175J/cm ²To about 300J/cm ²Energy density.

20. according to any one described method in the claim 1 to 4, wherein said NIMELS exit dose provides from about 200J/cm ²To about 250J/cm ²Energy density.

21. according to any one described method in the claim 1 to 4, wherein said NIMELS exit dose provides from about 300J/cm ²To about 700J/cm ²Energy density.

22. according to any one described method in the claim 1 to 4, wherein said NIMELS exit dose provides from about 300J/cm ²To about 500J/cm ²Energy density.

23. according to any one described method in the claim 1 to 4, wherein said NIMELS exit dose provides from about 300J/cm ²To about 450J/cm ²Energy density.